Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SFLMaven Corp. (SFLM)
Leamington Spa, GB
DNA Dynamics, Inc., operating through its subsidiaries, focuses on developing and distributing mobile applications and interactive entertainment for both smartphones and tablet devices. The company is proficient in creating and publishing games across Apple's iOS platform (including iPhone, iPad, and iPod touch) and Android, in addition to crafting various video games and applications for handheld consoles and other mobile devices. With a development footprint covering seven distinct platforms, DNA Dynamics also produces content for well-known television brands and intellectual property holders. The firm was founded in 1981 and maintains its corporate headquarters in Leamington Spa, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -75.00% | -98.29% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-100.0% Q2'23: -100.0% (vs Q1'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+100.0% ★ Q2'23: -111.9% (vs Q1'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q2'23: +1.5% (vs Q1'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+14.0% Q2'23: +11.1% (vs Q1'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.63× Q2'23: -4.43× (vs Q1'22)
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chad MacKay | Chief Executive Officer & Chairman of Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SFLM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
